Index DJIA, S&P 500
P/E 26.16
EPS (ttm) 6.05
Insider Own 0.12%
Shs Outstand 2.41B
Perf Week -2.08%
Market Cap 380.98B
Forward P/E 14.96
EPS next Y 10.58
Insider Trans -0.19%
Shs Float 2.40B
Perf Month -1.28%
Income 14.68B
PEG 7.93
EPS next Q 2.02
Inst Own 72.24%
Short Float 0.78%
Perf Quarter -0.46%
Sales 87.69B
P/S 4.34
EPS this Y 0.22%
Inst Trans 1.78%
Short Ratio 3.02
Perf Half Y 6.50%
Book/sh 29.14
P/B 5.43
EPS next Y 6.37%
ROA 8.58%
Short Interest 18.66M
Perf Year 5.32%
Cash/sh 8.43
P/C 18.77
EPS next 5Y 3.30%
ROE 20.89%
52W Range 143.13 - 168.85
Perf YTD 0.96%
Dividend Est. 4.68 (2.96%)
P/FCF 18.37
EPS past 5Y -0.27%
ROI 14.47%
52W High -6.28%
Beta 0.51
Dividend TTM 4.86 (3.07%)
Quick Ratio 0.79
Sales past 5Y 1.31%
Gross Margin 68.67%
52W Low 10.56%
ATR (14) 2.13
Dividend Ex-Date Nov 26, 2024
Current Ratio 1.03
EPS Y/Y TTM 15.10%
Oper. Margin 24.60%
RSI (14) 37.60
Volatility 1.15% 1.35%
Employees 131900
Debt/Eq 0.51
Sales Y/Y TTM -8.03%
Profit Margin 16.75%
Recom 2.18
Target Price 175.89
Option/Short Yes / Yes
LT Debt/Eq 0.45
EPS Q/Q -43.91%
Payout 84.93%
Rel Volume 0.75
Prev Close 160.13
Sales Surprise 1.35%
EPS Surprise 9.68%
Sales Q/Q 5.27%
Earnings Oct 15 BMO
Avg Volume 6.19M
Price 158.24
SMA20 -2.29%
SMA50 -3.01%
SMA200 1.36%
Trades
Volume 4,643,255
Change -1.18%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-23-24 Downgrade
Daiwa Securities
Outperform → Neutral
$160 → $150
May-30-24 Resumed
Goldman
Neutral
$160
Apr-18-24 Upgrade
HSBC Securities
Hold → Buy
$170
Dec-13-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$170 → $163
Dec-01-23 Upgrade
UBS
Neutral → Buy
$167 → $180
Oct-05-23 Initiated
RBC Capital Mkts
Outperform
$178
Sep-06-23 Initiated
HSBC Securities
Hold
$175
May-30-23 Resumed
Citigroup
Buy
$185
Mar-29-23 Initiated
UBS
Neutral
$164
Mar-01-23 Initiated
Guggenheim
Neutral
$161
Nov-18-22 Initiated
Credit Suisse
Neutral
$170
Oct-18-22 Initiated
Barclays
Equal Weight
$175
Oct-14-22 Reiterated
BofA Securities
Neutral
$185 → $178
Jun-22-22 Initiated
Daiwa Securities
Outperform
May-23-22 Resumed
SVB Leerink
Outperform
$200
Apr-06-22 Resumed
Morgan Stanley
Equal-Weight
$173
Mar-16-22 Downgrade
Bernstein
Outperform → Mkt Perform
$180 → $183
Mar-02-22 Resumed
BofA Securities
Neutral
$185
Dec-17-21 Initiated
Goldman
Neutral
$161
Dec-15-21 Reiterated
Citigroup
Buy
$192 → $195
Show Previous Ratings
Nov-04-24 06:35PM
03:11PM
Nov-01-24 08:35AM
07:47AM
Oct-31-24 04:00AM
(Pharmaceutical Technology)
09:19AM
Loading…
Oct-29-24 09:19AM
09:19AM
08:00AM
06:32AM
Oct-28-24 12:33PM
12:09PM
(The Wall Street Journal)
11:32AM
07:30AM
Oct-27-24 12:16PM
Oct-26-24 07:30AM
01:19PM
Loading…
Oct-25-24 01:19PM
08:05AM
05:37AM
Oct-24-24 01:28PM
10:26AM
(Design & Development Today)
08:00AM
08:00AM
05:21AM
04:00AM
01:02AM
Oct-23-24 05:03PM
(Pharmaceutical Technology)
09:00AM
04:30AM
Oct-22-24 01:13AM
Oct-21-24 05:03PM
03:33PM
Loading…
03:33PM
11:26AM
(Investor's Business Daily)
10:47AM
09:57AM
05:30AM
(The Wall Street Journal)
Oct-20-24 11:00AM
Oct-19-24 05:40PM
09:57AM
Oct-18-24 03:25PM
02:34PM
08:27AM
05:10AM
Oct-17-24 08:18AM
04:14AM
Oct-16-24 04:04PM
(Pharmaceutical Technology)
02:31PM
11:48AM
05:27AM
03:00AM
12:41AM
(Thomson Reuters StreetEvents)
Oct-15-24 07:05PM
06:08PM
06:06PM
04:07PM
(Investor's Business Daily)
04:06PM
03:45PM
03:26PM
02:30PM
01:39PM
12:46PM
11:39AM
11:07AM
(The Wall Street Journal)
10:56AM
10:09AM
10:09AM
09:41AM
(The Wall Street Journal)
09:30AM
08:20AM
08:09AM
08:03AM
(Investor's Business Daily)
08:00AM
08:00AM
07:35AM
07:11AM
06:32AM
(Associated Press Finance)
06:25AM
06:22AM
06:20AM
Oct-14-24 05:32PM
05:15PM
10:49AM
08:27AM
06:00AM
Oct-13-24 06:00AM
Oct-12-24 05:40AM
Oct-11-24 04:57PM
11:53AM
10:48AM
(Pharmaceutical Technology)
07:23AM
(The Wall Street Journal)
05:00AM
Oct-10-24 07:39PM
06:16PM
05:45PM
04:30PM
10:39AM
09:15AM
08:00AM
Oct-09-24 11:21AM
(Pharmaceutical Technology)
09:00AM
08:00AM
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Decker Robert J VP Corporate Controller Aug 30 '24 Option Exercise 100.06 5,635 563,838 24,608 Sep 03 04:48 PM Decker Robert J VP Corporate Controller Aug 30 '24 Sale 165.06 5,635 930,113 18,973 Sep 03 04:48 PM Decker Robert J Officer Aug 30 '24 Proposed Sale 165.06 5,635 930,113 Aug 30 03:51 PM Broadhurst Vanessa EVP, Global Corp Affairs Jul 08 '24 Option Exercise 0.00 9,809 0 24,852 Jul 09 05:48 PM REED JOHN C EVP, Innovative Medicine, R&D May 01 '24 Option Exercise 0.00 22,255 0 22,561 May 03 04:31 PM Broadhurst Vanessa EVP, Global Corp Affairs Mar 13 '24 Sale 162.16 8,891 1,441,765 15,043 Mar 13 04:36 PM JOHNSON & JOHNSON 10% Owner Feb 29 '24 Option Exercise 0.72 3,855 2,792 4,103,430 Mar 06 03:42 PM JOHNSON & JOHNSON 10% Owner Feb 16 '24 Sale 25.81 3,725 96,142 4,099,575 Mar 06 03:42 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Feb 13 '24 Option Exercise 0.00 651 0 82,599 Feb 15 04:53 PM Wolk Joseph J Exec VP, CFO Feb 13 '24 Option Exercise 0.00 1,780 0 69,663 Feb 15 04:53 PM Taubert Jennifer L EVP, WWC. Innovative Medicine Feb 13 '24 Option Exercise 0.00 1,302 0 155,517 Feb 15 04:53 PM Swanson James D. EVP, CIO Feb 13 '24 Option Exercise 0.00 447 0 14,765 Feb 15 04:53 PM Schmid Timothy EVP, WW Chair, MedTech Feb 13 '24 Option Exercise 0.00 499 0 13,290 Feb 15 04:53 PM Fasolo Peter Exec VP, Chief HR Officer Feb 13 '24 Option Exercise 0.00 925 0 112,550 Feb 15 04:53 PM Hait William See Remarks Feb 13 '24 Option Exercise 0.00 834 0 39,074 Feb 15 04:53 PM Duato Joaquin CEO and Chairman of the Board Feb 13 '24 Option Exercise 0.00 3,470 0 364,809 Feb 15 04:53 PM Broadhurst Vanessa EVP, Global Corp Affairs Feb 13 '24 Option Exercise 0.00 408 0 24,143 Feb 15 04:53 PM Forminard Elizabeth Executive VP, General Counsel Feb 13 '24 Option Exercise 0.00 651 0 8,576 Feb 15 04:53 PM Decker Robert J VP Corporate Controller Feb 13 '24 Option Exercise 0.00 313 0 19,059 Feb 15 04:53 PM Broadhurst Vanessa EVP, Global Corp Affairs Feb 12 '24 Option Exercise 0.00 4,701 0 25,081 Feb 14 06:36 PM Hait William See Remarks Feb 12 '24 Option Exercise 0.00 8,932 0 42,316 Feb 14 06:36 PM Wolk Joseph J Exec VP, CFO Feb 12 '24 Option Exercise 0.00 25,835 0 78,699 Feb 14 06:36 PM Forminard Elizabeth Executive VP, General Counsel Feb 12 '24 Option Exercise 0.00 2,859 0 8,959 Feb 14 06:36 PM Taubert Jennifer L EVP, WWC. Innovative Medicine Feb 12 '24 Option Exercise 0.00 26,202 0 167,618 Feb 14 06:36 PM Fasolo Peter Exec VP, Chief HR Officer Feb 12 '24 Option Exercise 0.00 14,960 0 118,644 Feb 14 06:36 PM Swanson James D. EVP, CIO Feb 12 '24 Option Exercise 0.00 5,456 0 16,013 Feb 14 06:36 PM Duato Joaquin CEO and Chairman of the Board Feb 12 '24 Option Exercise 0.00 36,618 0 377,239 Feb 14 06:36 PM Schmid Timothy EVP, WW Chair, MedTech Feb 12 '24 Option Exercise 0.00 5,736 0 15,678 Feb 14 06:36 PM Decker Robert J VP Corporate Controller Feb 12 '24 Option Exercise 0.00 1,912 0 19,269 Feb 14 06:36 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Feb 12 '24 Option Exercise 0.00 13,813 0 89,014 Feb 14 06:36 PM Duato Joaquin CEO and Chairman of the Board Feb 09 '24 Option Exercise 90.44 130,969 11,844,836 439,283 Feb 13 05:18 PM Taubert Jennifer L EVP, WW Chair, Pharmaceuticals Feb 09 '24 Option Exercise 90.44 59,397 5,371,865 200,813 Feb 12 07:25 PM Taubert Jennifer L EVP, WW Chair, Pharmaceuticals Feb 08 '24 Option Exercise 0.00 3,739 0 143,329 Feb 12 07:25 PM Taubert Jennifer L EVP, WW Chair, Pharmaceuticals Feb 09 '24 Sale 156.27 59,397 9,281,969 141,416 Feb 12 07:25 PM Duato Joaquin CEO and Chairman of the Board Feb 08 '24 Option Exercise 0.00 5,225 0 310,583 Feb 12 07:25 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Feb 08 '24 Option Exercise 0.00 1,971 0 67,905 Feb 12 07:25 PM Wolk Joseph J Exec VP, CFO Feb 08 '24 Option Exercise 0.00 3,686 0 53,911 Feb 12 07:25 PM Forminard Elizabeth Executive VP, General Counsel Feb 08 '24 Option Exercise 0.00 979 0 6,463 Feb 12 07:24 PM Swanson James D. See Remarks Feb 08 '24 Option Exercise 0.00 1,868 0 11,111 Feb 12 07:24 PM Schmid Timothy EVP, WW Chair, MedTech Feb 08 '24 Option Exercise 0.00 1,964 0 10,943 Feb 12 07:24 PM Fasolo Peter Exec VP, Chief HR Officer Feb 08 '24 Option Exercise 0.00 2,135 0 104,465 Feb 12 07:24 PM Hait William See Remarks Feb 08 '24 Option Exercise 0.00 3,059 0 34,497 Feb 12 07:24 PM Broadhurst Vanessa EVP, Global Corp Affairs Feb 08 '24 Option Exercise 0.00 1,880 0 21,083 Feb 12 07:24 PM Decker Robert J VP Corporate Controller Feb 08 '24 Option Exercise 0.00 655 0 17,572 Feb 12 07:24 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite